Progenics Finds New Partner For Relistor In Salix
This article was originally published in The Pink Sheet Daily
Executive Summary
A casualty of the Pfizer/Wyeth merger, Relistor rights bring Progenics $60 million upfront plus up to $290 million in milestones plus royalties.
You may also be interested in...
Relistor Expansion Plans In Question Following “Complete Response” Letter
FDA requested more clinical data on Salix/Progenics’ sNDA for approval of the subcutaneous formulation of methylnaltrexone in chronic, non-cancer pain patients with opioid-induced constipation. The regulatory setback could have implications for the companies’ planned September filing of an oral formulation in the same patient population.
Relistor Expansion Plans In Question Following “Complete Response” Letter
FDA requested more clinical data on Salix/Progenics’ sNDA for approval of the subcutaneous formulation of methylnaltrexone in chronic, non-cancer pain patients with opioid-induced constipation. The regulatory setback could have implications for the companies’ planned September filing of an oral formulation in the same patient population.
Relistor Expansion Plans In Question Following “Complete Response” Letter
FDA requested more clinical data on Salix/Progenics’ sNDA for approval of the subcutaneous formulation of methylnaltrexone in chronic, non-cancer pain patients with opioid-induced constipation. The regulatory setback could have implications for the companies’ planned September filing of an oral formulation in the same patient population.